SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 222 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $342 | -8.3% | 12,416 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $373 | -17.1% | 12,416 | 0.0% | 0.00% | -33.3% |
| Q1 2023 | $450 | +1.6% | 12,416 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $443 | -99.9% | 12,416 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $420,000 | +17.0% | 12,416 | 0.0% | 0.00% | +50.0% |
| Q2 2022 | $359,000 | -10.5% | 12,416 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $401,000 | -17.3% | 12,416 | -25.3% | 0.00% | 0.0% |
| Q4 2021 | $485,000 | +9.5% | 16,616 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $443,000 | -13.5% | 16,616 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $512,000 | +95.4% | 16,616 | +65.9% | 0.00% | +200.0% |
| Q1 2021 | $262,000 | +4.0% | 10,016 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $252,000 | +20.6% | 10,016 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $209,000 | -56.1% | 10,016 | -50.0% | 0.00% | 0.0% |
| Q2 2020 | $476,000 | – | 20,032 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |